{"id":346052,"date":"2026-11-13T10:19:23","date_gmt":"2026-11-13T04:49:23","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=346052"},"modified":"2026-11-13T10:19:23","modified_gmt":"2026-11-13T04:49:23","slug":"wind-turbines-maker-footwear-brand-company-and-pharmaceutical-company-stocks-roadmap-uplands-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/wind-turbines-maker-footwear-brand-company-and-pharmaceutical-company-stocks-roadmap-uplands-list\/","title":{"rendered":"3 Wind Turbines Maker, Footwear Brand Company and Pharmaceutical Company Stocks With a Strong Future Roadmap: Suzlon Energy, Redtape and Cipla"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Suzlon Energy, Redtape and Cipla: ROE of 11.3% to 33.4% and FY22 to FY26 revenue CAGR of 7.1% to 70.3%. Prices as of 12 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three wind turbine, footwear and pharma stocks to watch are Suzlon Energy, Redtape and Cipla. Their return on equity ranges from 11.3% to 33.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.1% to 70.3%. Suzlon Energy has the highest return on equity at 33.4%, while Redtape has the fastest revenue growth at 70.3% a year. Prices are based on the 12 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Wind turbine, footwear and pharma stocks give investors a way to track businesses that sit close to everyday demand in India. Suzlon Energy, Redtape and Cipla cover a wind turbines maker, a footwear brand company and a pharmaceutical company.<\/p>\n<p>This list covers three wind turbine, footwear and pharma stocks with complete current figures: Suzlon Energy, Redtape and Cipla. Every figure comes from the latest reported financials and the 12 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=wind-turbines-maker-footwear-brand-company-and-pharmaceutical-company-stocks-roadmap-uplands-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/wind-turbines-maker-footwear-brand-company-and-pharmaceutical-company-stocks-roadmap-uplands-list\/#What_Are_Wind_Turbine_Footwear_and_Pharma_Stocks\" title=\"What Are Wind Turbine, Footwear and Pharma Stocks?\">What Are Wind Turbine, Footwear and Pharma Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/wind-turbines-maker-footwear-brand-company-and-pharmaceutical-company-stocks-roadmap-uplands-list\/#Wind_Turbine_Footwear_and_Pharma_Stocks_at_a_Glance\" title=\"Wind Turbine, Footwear and Pharma Stocks at a Glance\">Wind Turbine, Footwear and Pharma Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/wind-turbines-maker-footwear-brand-company-and-pharmaceutical-company-stocks-roadmap-uplands-list\/#Why_Do_Wind_Turbine_Footwear_and_Pharma_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Wind Turbine, Footwear and Pharma Stocks Have a Strong Roadmap in India?\">Why Do Wind Turbine, Footwear and Pharma Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/wind-turbines-maker-footwear-brand-company-and-pharmaceutical-company-stocks-roadmap-uplands-list\/#Why_Suzlon_Energy_Features_Among_These_Wind_Turbine_Footwear_and_Pharma_Stocks\" title=\"Why Suzlon Energy Features Among These Wind Turbine, Footwear and Pharma Stocks\">Why Suzlon Energy Features Among These Wind Turbine, Footwear and Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/wind-turbines-maker-footwear-brand-company-and-pharmaceutical-company-stocks-roadmap-uplands-list\/#Why_Redtape_Features_Among_These_Wind_Turbine_Footwear_and_Pharma_Stocks\" title=\"Why Redtape Features Among These Wind Turbine, Footwear and Pharma Stocks\">Why Redtape Features Among These Wind Turbine, Footwear and Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/wind-turbines-maker-footwear-brand-company-and-pharmaceutical-company-stocks-roadmap-uplands-list\/#Why_Cipla_Features_Among_These_Wind_Turbine_Footwear_and_Pharma_Stocks\" title=\"Why Cipla Features Among These Wind Turbine, Footwear and Pharma Stocks\">Why Cipla Features Among These Wind Turbine, Footwear and Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/wind-turbines-maker-footwear-brand-company-and-pharmaceutical-company-stocks-roadmap-uplands-list\/#Suzlon_Energy_vs_Redtape_vs_Cipla_on_Key_Financials\" title=\"Suzlon Energy vs Redtape vs Cipla on Key Financials\">Suzlon Energy vs Redtape vs Cipla on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/wind-turbines-maker-footwear-brand-company-and-pharmaceutical-company-stocks-roadmap-uplands-list\/#Key_Risks_to_Check_Before_Investing_in_Wind_Turbine_Footwear_and_Pharma_Stocks\" title=\"Key Risks to Check Before Investing in Wind Turbine, Footwear and Pharma Stocks\">Key Risks to Check Before Investing in Wind Turbine, Footwear and Pharma Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/wind-turbines-maker-footwear-brand-company-and-pharmaceutical-company-stocks-roadmap-uplands-list\/#Final_Thoughts_on_Wind_Turbine_Footwear_and_Pharma_Stocks\" title=\"Final Thoughts on Wind Turbine, Footwear and Pharma Stocks\">Final Thoughts on Wind Turbine, Footwear and Pharma Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/wind-turbines-maker-footwear-brand-company-and-pharmaceutical-company-stocks-roadmap-uplands-list\/#What_are_wind_turbine_footwear_and_pharma_stocks\" title=\"What are wind turbine, footwear and pharma stocks?\">What are wind turbine, footwear and pharma stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/wind-turbines-maker-footwear-brand-company-and-pharmaceutical-company-stocks-roadmap-uplands-list\/#Which_wind_turbine_footwear_and_pharma_stocks_are_covered_in_this_list\" title=\"Which wind turbine, footwear and pharma stocks are covered in this list?\">Which wind turbine, footwear and pharma stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/wind-turbines-maker-footwear-brand-company-and-pharmaceutical-company-stocks-roadmap-uplands-list\/#Why_do_wind_turbine_footwear_and_pharma_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do wind turbine, footwear and pharma stocks have a strong future roadmap in India?\">Why do wind turbine, footwear and pharma stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/wind-turbines-maker-footwear-brand-company-and-pharmaceutical-company-stocks-roadmap-uplands-list\/#How_has_Suzlon_Energy_performed_financially\" title=\"How has Suzlon Energy performed financially?\">How has Suzlon Energy performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/wind-turbines-maker-footwear-brand-company-and-pharmaceutical-company-stocks-roadmap-uplands-list\/#How_has_Redtape_performed_financially\" title=\"How has Redtape performed financially?\">How has Redtape performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/wind-turbines-maker-footwear-brand-company-and-pharmaceutical-company-stocks-roadmap-uplands-list\/#How_has_Cipla_performed_financially\" title=\"How has Cipla performed financially?\">How has Cipla performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/wind-turbines-maker-footwear-brand-company-and-pharmaceutical-company-stocks-roadmap-uplands-list\/#What_risks_should_investors_check_before_buying_wind_turbine_footwear_and_pharma_stocks\" title=\"What risks should investors check before buying wind turbine, footwear and pharma stocks?\">What risks should investors check before buying wind turbine, footwear and pharma stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/wind-turbines-maker-footwear-brand-company-and-pharmaceutical-company-stocks-roadmap-uplands-list\/#Is_this_list_of_wind_turbine_footwear_and_pharma_stocks_investment_advice\" title=\"Is this list of wind turbine, footwear and pharma stocks investment advice?\">Is this list of wind turbine, footwear and pharma stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Wind_Turbine_Footwear_and_Pharma_Stocks\"><\/span><strong>What Are Wind Turbine, Footwear and Pharma Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Wind turbine, footwear and pharma stocks are listed companies that build wind turbines and offer wind farm services, sell casual and formal footwear through stores and online, and make and sell branded and generic medicines for breathing, heart and other care. Their earnings depend on wind capacity additions, consumer spending and prescription demand.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Wind_Turbine_Footwear_and_Pharma_Stocks_at_a_Glance\"><\/span><strong>Wind Turbine, Footwear and Pharma Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/suzlon\/suzlon-energy-ltd-share-price-today\">Suzlon Energy<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">38.86<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">55,008<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">43.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.06<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/redtape\/redtape-ltd-share-price-today\">Redtape<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">108.56<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">6,169<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">25.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">63.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.70<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/cipla\/cipla-ltd-share-price-today\">Cipla<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,408.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">107,528<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">32.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.02<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, all three trade at a P\/E below their industry P\/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing wind turbine, footwear and pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Wind_Turbine_Footwear_and_Pharma_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Wind Turbine, Footwear and Pharma Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Wind turbine, footwear and pharma stocks have a strong roadmap in India because rapid renewable capacity additions, rising demand for branded footwear and steady demand for quality medicines keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Wind turbines.<\/strong> Utilities add clean energy capacity.<\/li>\n<li><strong>Footwear.<\/strong> Shoppers upgrade to branded footwear.<\/li>\n<li><strong>Pharma.<\/strong> Branded and generic medicines reach more markets.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Suzlon_Energy_Features_Among_These_Wind_Turbine_Footwear_and_Pharma_Stocks\"><\/span><strong>Why Suzlon Energy Features Among These Wind Turbine, Footwear and Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the wind turbine, footwear and pharma stocks on this list, Suzlon Energy is a wind turbine maker with manufacturing and service operations across India, supplying turbines for utility, independent power producer and corporate customers and servicing a large installed base.<\/p>\n<p>In the June 2026 quarter, revenue grew 22.0% year on year to Rs 3,863 crore. Revenue rose from Rs 6,604 crore in FY22 to Rs 16,842 crore in FY26, a compound annual growth rate of 26.4%.<\/p>\n<p>Net profit grew from Rs 2,072 crore in FY25 to Rs 3,163 crore in FY26, a rise of 52.7%. The company has a return on equity of 33.4%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 55,008 crore. The stock trades at a P\/E of 17.5, below the industry P\/E of 43.9.<\/p>\n<p><strong>Roadmap:<\/strong> The company has a large order book and a strong share of the domestic wind market as the country adds renewable capacity. Its operations and maintenance business generates recurring income from the installed fleet.<\/p>\n<p><strong>What to watch:<\/strong> Check order book conversion to revenue and the pace of turbine deliveries each quarter.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Redtape_Features_Among_These_Wind_Turbine_Footwear_and_Pharma_Stocks\"><\/span><strong>Why Redtape Features Among These Wind Turbine, Footwear and Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the renewable power, shoe brand and medicine shares on this list, Redtape, an Indian footwear and accessories brand, sells casual, formal and sports footwear through exclusive stores, multi-brand outlets and online channels.<\/p>\n<p>The company has a return on equity of 23.6%, a debt to equity ratio of 0.70 and a market capitalisation of Rs 6,169 crore. The stock trades at a P\/E of 25.0, below the industry P\/E of 63.4.<\/p>\n<p>Revenue rose from Rs 303 crore in FY22 to Rs 2,552 crore in FY26, a compound annual growth rate of 70.3%. Net profit grew from Rs 29.0 crore in FY22 to Rs 241 crore in FY26, which works out to a compound annual growth rate of 69.6%. In the June 2026 quarter, revenue grew 4.8% year on year to Rs 496 crore, while net profit rose 15.2% to Rs 44.5 crore.<\/p>\n<p><strong>Roadmap:<\/strong> Growth is driven by store expansion, higher online sales and a broader product range, including apparel and accessories. A shift towards branded footwear in smaller cities widens its customer base.<\/p>\n<p><strong>What to watch:<\/strong> Follow same-store sales and the pace of new store openings.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Cipla_Features_Among_These_Wind_Turbine_Footwear_and_Pharma_Stocks\"><\/span><strong>Why Cipla Features Among These Wind Turbine, Footwear and Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Cipla is a Mumbai-based pharmaceutical company with strengths in respiratory medicines, anti-infectives and chronic therapies. It sells branded and generic products in India, South Africa, the United States and other markets.<\/p>\n<p>Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%.<\/p>\n<p>In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P\/E of 32.0, below the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.<\/p>\n<p><strong>What to watch:<\/strong> Follow new product launches in the United States and the growth of key domestic brands.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Suzlon_Energy_vs_Redtape_vs_Cipla_on_Key_Financials\"><\/span><strong>Suzlon Energy vs Redtape vs Cipla on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three wind turbine, footwear and pharma stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Suzlon Energy<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">6,604<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16,842<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">26.4%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,163<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Redtape<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">303<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,552<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">70.3%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">241<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9.4%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Cipla<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22,044<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">29,045<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,870<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.3%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Suzlon Energy posts the highest return on equity in this group at 33.4%. Cipla has the largest FY26 revenue at Rs 29,045 crore, and Redtape shows the fastest revenue growth with a 70.3% compound annual rate. A useful habit with wind turbine, footwear and pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<p>The June 2026 quarter, the latest reported, gives a fresh read on momentum:<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY27 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Year-on-Year Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Suzlon Energy<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,165<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,863<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">22.0%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Redtape<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">473<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">496<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Cipla<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7,216<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7,330<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1.6%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Wind_Turbine_Footwear_and_Pharma_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Wind Turbine, Footwear and Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these wind turbine, footwear and pharma stocks, the main points are: Long-term renewable power, shoe brand and medicine shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Module prices.<\/strong> Solar equipment prices and policy support can change returns.<\/li>\n<li><strong>Footfall and spending.<\/strong> Store sales follow consumer mood and seasons.<\/li>\n<li><strong>Pricing pressure.<\/strong> Generic prices can change by market.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter wind turbine, footwear and pharma stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Wind_Turbine_Footwear_and_Pharma_Stocks\"><\/span><strong>Final Thoughts on Wind Turbine, Footwear and Pharma Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Wind turbine, footwear and pharma stocks work best when investors track growth, valuation and return on equity side by side. Suzlon Energy, Redtape and Cipla each have a clear plan to grow. Based on the 12 November 2026 close, Suzlon Energy trades at Rs 38.86, Redtape at Rs 108.56 and Cipla at Rs 1,408.3. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these wind turbine, footwear and pharma stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track wind turbine, footwear and pharma stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_wind_turbine_footwear_and_pharma_stocks\"><\/span><strong>What are wind turbine, footwear and pharma stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Wind turbine, footwear and pharma stocks are listed companies that build wind turbines and offer wind farm services, sell casual and formal footwear through stores and online, and make and sell branded and generic medicines for breathing, heart and other care. Their earnings depend on wind capacity additions, consumer spending and prescription demand. This list looks at three of them, Suzlon Energy, Redtape and Cipla, using reported FY22 to FY26 financials and the 12 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_wind_turbine_footwear_and_pharma_stocks_are_covered_in_this_list\"><\/span><strong>Which wind turbine, footwear and pharma stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Suzlon Energy, Redtape and Cipla. Based on the 12 November 2026 close, Suzlon Energy traded at Rs 38.86, Redtape at Rs 108.56 and Cipla at Rs 1,408.3. Their return on equity ranges from 11.3% to 33.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.1% to 70.3%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_wind_turbine_footwear_and_pharma_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do wind turbine, footwear and pharma stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Wind turbine, footwear and pharma stocks have a strong roadmap in India because rapid renewable capacity additions, rising demand for branded footwear and steady demand for quality medicines keep widening the market for these companies. The main drivers are as follows. Wind turbines. Utilities add clean energy capacity. Footwear. Shoppers upgrade to branded footwear. Pharma. Branded and generic medicines reach more markets. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Suzlon_Energy_performed_financially\"><\/span><strong>How has Suzlon Energy performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 6,604 crore in FY22 to Rs 16,842 crore in FY26, a compound annual growth rate of 26.4%. Net profit grew from Rs 2,072 crore in FY25 to Rs 3,163 crore in FY26, a rise of 52.7%. In the June 2026 quarter, revenue grew 22.0% year on year to Rs 3,863 crore. The company has a return on equity of 33.4%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 55,008 crore. The stock trades at a P\/E of 17.5, below the industry P\/E of 43.9. Looking ahead, the company has a large order book and a strong share of the domestic wind market as the country adds renewable capacity. Its operations and maintenance business generates recurring income from the installed fleet.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Redtape_performed_financially\"><\/span><strong>How has Redtape performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 303 crore in FY22 to Rs 2,552 crore in FY26, a compound annual growth rate of 70.3%. Net profit grew from Rs 29.0 crore in FY22 to Rs 241 crore in FY26, which works out to a compound annual growth rate of 69.6%. In the June 2026 quarter, revenue grew 4.8% year on year to Rs 496 crore, while net profit rose 15.2% to Rs 44.5 crore. The company has a return on equity of 23.6%, a debt to equity ratio of 0.70 and a market capitalisation of Rs 6,169 crore. The stock trades at a P\/E of 25.0, below the industry P\/E of 63.4. Looking ahead, growth is driven by store expansion, higher online sales and a broader product range, including apparel and accessories. A shift towards branded footwear in smaller cities widens its customer base.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Cipla_performed_financially\"><\/span><strong>How has Cipla performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P\/E of 32.0, below the industry P\/E of 36.0. Looking ahead, the company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_wind_turbine_footwear_and_pharma_stocks\"><\/span><strong>What risks should investors check before buying wind turbine, footwear and pharma stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying wind turbine, footwear and pharma stocks. Module prices. Solar equipment prices and policy support can change returns. Footfall and spending. Store sales follow consumer mood and seasons. Pricing pressure. Generic prices can change by market. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_wind_turbine_footwear_and_pharma_stocks_investment_advice\"><\/span><strong>Is this list of wind turbine, footwear and pharma stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 12 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are wind turbine, footwear and pharma stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Wind turbine, footwear and pharma stocks are listed companies that build wind turbines and offer wind farm services, sell casual and formal footwear through stores and online, and make and sell branded and generic medicines for breathing, heart and other care. Their earnings depend on wind capacity additions, consumer spending and prescription demand. This list looks at three of them, Suzlon Energy, Redtape and Cipla, using reported FY22 to FY26 financials and the 12 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which wind turbine, footwear and pharma stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Suzlon Energy, Redtape and Cipla. Based on the 12 November 2026 close, Suzlon Energy traded at Rs 38.86, Redtape at Rs 108.56 and Cipla at Rs 1,408.3. Their return on equity ranges from 11.3% to 33.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.1% to 70.3%.\"}},{\"@type\":\"Question\",\"name\":\"Why do wind turbine, footwear and pharma stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Wind turbine, footwear and pharma stocks have a strong roadmap in India because rapid renewable capacity additions, rising demand for branded footwear and steady demand for quality medicines keep widening the market for these companies. The main drivers are as follows. Wind turbines. Utilities add clean energy capacity. Footwear. Shoppers upgrade to branded footwear. Pharma. Branded and generic medicines reach more markets. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Suzlon Energy performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 6,604 crore in FY22 to Rs 16,842 crore in FY26, a compound annual growth rate of 26.4%. Net profit grew from Rs 2,072 crore in FY25 to Rs 3,163 crore in FY26, a rise of 52.7%. In the June 2026 quarter, revenue grew 22.0% year on year to Rs 3,863 crore. The company has a return on equity of 33.4%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 55,008 crore. The stock trades at a P\/E of 17.5, below the industry P\/E of 43.9. Looking ahead, the company has a large order book and a strong share of the domestic wind market as the country adds renewable capacity. Its operations and maintenance business generates recurring income from the installed fleet.\"}},{\"@type\":\"Question\",\"name\":\"How has Redtape performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 303 crore in FY22 to Rs 2,552 crore in FY26, a compound annual growth rate of 70.3%. Net profit grew from Rs 29.0 crore in FY22 to Rs 241 crore in FY26, which works out to a compound annual growth rate of 69.6%. In the June 2026 quarter, revenue grew 4.8% year on year to Rs 496 crore, while net profit rose 15.2% to Rs 44.5 crore. The company has a return on equity of 23.6%, a debt to equity ratio of 0.70 and a market capitalisation of Rs 6,169 crore. The stock trades at a P\/E of 25.0, below the industry P\/E of 63.4. Looking ahead, growth is driven by store expansion, higher online sales and a broader product range, including apparel and accessories. A shift towards branded footwear in smaller cities widens its customer base.\"}},{\"@type\":\"Question\",\"name\":\"How has Cipla performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P\/E of 32.0, below the industry P\/E of 36.0. Looking ahead, the company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying wind turbine, footwear and pharma stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying wind turbine, footwear and pharma stocks. Module prices. Solar equipment prices and policy support can change returns. Footfall and spending. Store sales follow consumer mood and seasons. Pricing pressure. Generic prices can change by market. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of wind turbine, footwear and pharma stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 12 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Wind Turbine, Footwear and Pharma Stocks with a strong future roadmap: Suzlon Energy, Redtape and Cipla. Compare price, valuation, return on equity and revenue growth as of 12 November 2026.<\/p>\n","protected":false},"author":34,"featured_media":346051,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,23303,3792,23300,11013,23301,23302,2534,22097,18101],"class_list":["post-346052","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-casual-footwear-and-respiratory-drug-stocks","tag-cipla","tag-footwear-and-pharma-stocks","tag-redtape","tag-renewable-power","tag-shoe-brand-and-medicine-shares","tag-suzlon-energy","tag-turbine-maker","tag-wind-turbine"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["346051"],"rank_math_title":["Wind Turbine, Footwear and Pharma Stocks"],"rank_math_description":["Compare 3 wind turbine, footwear and pharma stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 12 Nov 2026."],"rank_math_focus_keyword":["wind turbine, footwear and pharma stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-wind-turbines-maker-footwear-brand-company-and-pharmaceutical-company-stocks.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/346052","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=346052"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/346052\/revisions"}],"predecessor-version":[{"id":346053,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/346052\/revisions\/346053"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/346051"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=346052"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=346052"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=346052"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}